Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers

Radhakrishnan, Vivek; Swanson, Mark S.; Sinha, Uttam K.

doi:10.3934/medsci.2015.4.347

Cited by 2 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together, these problems highlight the need of novel diagnostic methods with the high sensitivity of 18 F-FDG-PET and increased tumor specificity. In HNSCC, targeted therapy or antibody-mediated diagnostic methods hold particular promise to improve early detection [ 24 ] and to treat minimal residual disease [ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches

Spiegelberg

Nilvebrant

2017

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is a common and severe cancer with low survival rate in advanced stages. Noninvasive imaging of prognostic and therapeutic biomarkers could provide valuable information for planning and monitoring of the different therapy options. Thus, there is a major interest in development of new tracers towards cancer-specific molecular targets to improve diagnostic imaging and treatment. CD44v6, an oncogenic variant of the cell surface molecule CD44, is a promising molecular target since it exhibits a unique expression pattern in HNSCC and is associated with drug- and radio-resistance. In this review we summarize results from preclinical and clinical investigations of radiolabeled anti-CD44v6 antibody-based tracers: full-length antibodies, Fab, F(ab′)2 fragments, and scFvs with particular focus on the engineering of various antibody formats and choice of radiolabel for the use as molecular imaging agents in HNSCC. We conclude that the current evidence points to CD44v6 imaging being a promising approach for providing more specific and sensitive diagnostic tools, leading to customized treatment decisions and functional diagnosis. Improved imaging tools hold promise to enable more effective treatment for head and neck cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches

Spiegelberg

Nilvebrant

2017

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

Immunotherapy

Sahu

Suryawanshi

2021

Journal of Oral and Maxillofacial Pathology

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCCs) are one of the most common cancers worldwide. A large number of patients are diagnosed with locally advanced disease and require multimodal treatment approaches. Standard treatment modalities ranging from surgery to chemotherapy and radiation are yielding mixed results. To overcome this hurdle, newer innovative approaches are required to reduce the morbidity and mortality of the patients. In the last few decades, immunotherapy has become an important part of treating some types of cancer. The immune system plays a key role in the development, establishment and progression of HNSCC. A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of HNSCC provides the basis for improved therapies and outcomes for patients. Newer types of immune treatments are now being studied, and they will impact how we treat cancer in the future. This article provides a brief overview of the current immunotherapeutic strategies for cancer with emphasis on HNSCC.

show abstract

Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers

Cited by 2 publications

References 49 publications

CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches

CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches

Immunotherapy

Contact Info

Product

Resources

About